Could an Emerging AI Platform Supplant Traditional MRI for Assessing Prostate Cancer?
The Food and Drug Administration has granted 510(k) clearance to iQuest (Avenda Health), an artificial intelligence (AI) platform that combines findings from magnetic resonance imaging (MRI), pathology reports and biopsy results to facilitate three-dimensional mapping of prostate cancer.
iQuest™ (Avenda Health), an artificial intelligence (AI)-powered platform that may facilitate more precise imaging of prostate cancer beyond traditional magnetic resonance imaging (MRI), has garnered 510(k) clearance from the Food and Drug Administration (FDA).
Avenda Health said the iQuest precision oncology platform utilizes deep learning algorithms and a variety of existing diagnostic data from a patient’s MRI and biopsy results to create three-dimensional (3D) mapping of prostate cancer. Noting that current MRI technology significantly underestimates prostate cancer disease, Avenda Health said the 3D visualization with iQuest gives providers an enhanced understanding of the extent and growth of prostate tumors.
In a recent interview with OncologyLive, Brittany Berry-Pusey, PhD, a co-founder and chief operating officer of Avenda Health, said the iQuest system helps identify tumor margins and calculates “voxel-level probability of clinically significant prostate cancer.”
Research with the iQuest platform has reportedly demonstrated a 60 percent improvement in sensitivity for identifying the extent of prostate cancer tumors and subsequent changes in treatment recommendations in 27 percent of cases, according to Avenda Health.
“We are excited about the potential to unlock precision care in prostate cancer with iQuest as it is a key enabling technology for focal therapy to be a reality … ,” noted Shyam Natarajan, Ph.D., a co-founder and CEO of Avenda Health. “In order for a doctor to treat focally, they need to know where cancer is and the healthy tissue to avoid. This is vital information that iQuest now provides. This is a huge step forward in transforming the standard of care in prostate cancer.”
References
1. Avenda Health. First AI-powered precision oncology platform for prostate cancer care, iQuest™, receives FDA clearance. Cision PR Newswire. Available at: https://www.prnewswire.com/news-releases/first-ai-powered-precision-oncology-platform-for-prostate-cancer-care-iquesttm-receives-fda-clearance-301696475.html . Published December 7, 2022. Accessed December 7, 2022.
2. Doherty K. AI-powered focal therapy maps future treatment paradigm in prostate cancer. OncologyLive. Available at: https://www.onclive.com/view/ai-powered-focal-therapy-maps-future-treatment-paradigm-in-prostate-cancer . Published September 8, 2022. Accessed December 7, 2022.
Can CT-Based Deep Learning Bolster Prognostic Assessments of Ground-Glass Nodules?
June 19th 2025Emerging research shows that a multiple time-series deep learning model assessment of CT images provides 20 percent higher sensitivity than a delta radiomic model and 56 percent higher sensitivity than a clinical model for prognostic evaluation of ground-glass nodules.
Can Contrast-Enhanced Mammography be a Viable Screening Alternative to Breast MRI?
June 17th 2025While the addition of contrast-enhanced mammography (CEM) to digital breast tomosynthesis (DBT) led to over a 13 percent increase in false positive cases, researchers also noted over double the cancer yield per 1,000 women in comparison to DBT alone.
Multinational Study Reaffirms Value of Adjunctive AI for Prostate MRI
June 16th 2025The use of adjunctive AI in biparametric prostate MRI exams led to 3.3 percent and 3.4 percent increases in the AUC and specificity, respectively, for clinically significant prostate cancer (csPCa) in a 360-person cohort drawn from 53 facilities.
